Clinical trial
Vaccine Therapy in Treating Patients With Refractory Metastatic Melanoma
NCT00020397 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00020397 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Refractory Metastatic Melanoma |
| Official title | Immunization Of HLA-A*0201 or HLA-DPB1*04 Patients With Metastatic Melanoma Using Epitopes From The ESO-1 Antigen |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | NY-ESO-1 peptide vaccine, aldesleukin |
| Start date | Nov 1, 2000 |
| Completion | Jul 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: